201 related articles for article (PubMed ID: 11751379)
1. Loss of heterozygosity of the putative prostate cancer susceptibility gene HPC2/ELAC2 is uncommon in sporadic and familial prostate cancer.
Wu YQ; Chen H; Rubin MA; Wojno KJ; Cooney KA
Cancer Res; 2001 Dec; 61(24):8651-3. PubMed ID: 11751379
[TBL] [Abstract][Full Text] [Related]
2. Role of HPC2/ELAC2 in hereditary prostate cancer.
Wang L; McDonnell SK; Elkins DA; Slager SL; Christensen E; Marks AF; Cunningham JM; Peterson BJ; Jacobsen SJ; Cerhan JR; Blute ML; Schaid DJ; Thibodeau SN
Cancer Res; 2001 Sep; 61(17):6494-9. PubMed ID: 11522646
[TBL] [Abstract][Full Text] [Related]
3. Polymorphisms in the prostate cancer susceptibility gene HPC2/ELAC2 in multiplex families and healthy controls.
Suarez BK; Gerhard DS; Lin J; Haberer B; Nguyen L; Kesterson NK; Catalona WJ
Cancer Res; 2001 Jul; 61(13):4982-4. PubMed ID: 11431329
[TBL] [Abstract][Full Text] [Related]
4. ELAC2/HPC2 involvement in hereditary and sporadic prostate cancer.
Rökman A; Ikonen T; Mononen N; Autio V; Matikainen MP; Koivisto PA; Tammela TL; Kallioniemi OP; Schleutker J
Cancer Res; 2001 Aug; 61(16):6038-41. PubMed ID: 11507049
[TBL] [Abstract][Full Text] [Related]
5. Mutational analysis of susceptibility genes RNASEL/HPC1, ELAC2/HPC2, and MSR1 in sporadic prostate cancer.
Nupponen NN; Wallén MJ; Ponciano D; Robbins CM; Tammela TL; Vessella RL; Carpten JD; Visakorpi T
Genes Chromosomes Cancer; 2004 Feb; 39(2):119-25. PubMed ID: 14695991
[TBL] [Abstract][Full Text] [Related]
6. A region close to Tp53 shows LOH in familial breast cancer.
Luo L; Chen J; Du Q; Dumanski J; Blennow E; Kockum I; Luthman H; Lindblom A
Int J Mol Med; 2002 Apr; 9(4):405-9. PubMed ID: 11891537
[TBL] [Abstract][Full Text] [Related]
7. HPC2/ELAC2 polymorphism associated with Japanese sporadic prostate cancer.
Yokomizo A; Koga H; Kinukawa N; Tsukamoto T; Hirao Y; Akaza H; Mori M; Naito S
Prostate; 2004 Nov; 61(3):248-52. PubMed ID: 15368467
[TBL] [Abstract][Full Text] [Related]
8. Loss of heterozygosity of M6P/IGF2R gene is an early event in the development of prostate cancer.
Hu CK; McCall S; Madden J; Huang H; Clough R; Jirtle RL; Anscher MS
Prostate Cancer Prostatic Dis; 2006; 9(1):62-7. PubMed ID: 16304558
[TBL] [Abstract][Full Text] [Related]
9. Limiting the location of putative human prostate cancer tumor suppressor genes on chromosome 18q.
Yin Z; Babaian RJ; Troncoso P; Strom SS; Spitz MR; Caudell JJ; Stein JD; Kagan J
Oncogene; 2001 Apr; 20(18):2273-80. PubMed ID: 11402322
[TBL] [Abstract][Full Text] [Related]
10. Association of HPC2/ELAC2 polymorphism with prostate cancer risk in a Japanese population.
Suzuki K; Ohtake N; Nakata S; Takei T; Matsui H; Ono Y; Nakazato H; Hasumi M; Koike H; Ito K; Fukabori Y; Kurokawa K; Yamanaka H
Anticancer Res; 2002; 22(6B):3507-11. PubMed ID: 12552947
[TBL] [Abstract][Full Text] [Related]
11. Association of common missense changes in ELAC2 ( HPC2) with prostate cancer in a Japanese case-control series.
Fujiwara H; Emi M; Nagai H; Nishimura T; Konishi N; Kubota Y; Ichikawa T; Takahashi S; Shuin T; Habuchi T; Ogawa O; Inoue K; Skolnick MH; Swensen J; Camp NJ; Tavtigian SV
J Hum Genet; 2002; 47(12):641-8. PubMed ID: 12522685
[TBL] [Abstract][Full Text] [Related]
12. An 800-kb region of deletion at 13q14 in human prostate and other carcinomas.
Chen C; Frierson HF; Haggerty PF; Theodorescu D; Gregory CW; Dong JT
Genomics; 2001 Oct; 77(3):135-44. PubMed ID: 11597138
[TBL] [Abstract][Full Text] [Related]
13. Distinct regions of allelic loss on 13q in prostate cancer.
Cooney KA; Wetzel JC; Merajver SD; Macoska JA; Singleton TP; Wojno KJ
Cancer Res; 1996 Mar; 56(5):1142-5. PubMed ID: 8640774
[TBL] [Abstract][Full Text] [Related]
14. Prevalent mutations in prostate cancer.
Dong JT
J Cell Biochem; 2006 Feb; 97(3):433-47. PubMed ID: 16267836
[TBL] [Abstract][Full Text] [Related]
15. Limiting the location of a putative human prostate cancer tumor suppressor gene at chromosome 13q14.3.
Yin Z; Spitz MR; Babaian RJ; Strom SS; Troncoso P; Kagan J
Oncogene; 1999 Dec; 18(52):7576-83. PubMed ID: 10602517
[TBL] [Abstract][Full Text] [Related]
16. Genome linkage screen for prostate cancer susceptibility loci: results from the Mayo Clinic Familial Prostate Cancer Study.
Cunningham JM; McDonnell SK; Marks A; Hebbring S; Anderson SA; Peterson BJ; Slager S; French A; Blute ML; Schaid DJ; Thibodeau SN;
Prostate; 2003 Dec; 57(4):335-46. PubMed ID: 14601030
[TBL] [Abstract][Full Text] [Related]
17. Involvement of the RNAse L gene in prostate cancer.
Kieffer N; Schmitz M; Scheiden R; Nathan M; Faber JC
Bull Soc Sci Med Grand Duche Luxemb; 2006; (1):21-8. PubMed ID: 16869093
[TBL] [Abstract][Full Text] [Related]
18. Evaluation of linkage and association of HPC2/ELAC2 in patients with familial or sporadic prostate cancer.
Xu J; Zheng SL; Carpten JD; Nupponen NN; Robbins CM; Mestre J; Moses TY; Faith DA; Kelly BD; Isaacs SD; Wiley KE; Ewing CM; Bujnovszky P; Chang B; Bailey-Wilson J; Bleecker ER; Walsh PC; Trent JM; Meyers DA; Isaacs WB
Am J Hum Genet; 2001 Apr; 68(4):901-11. PubMed ID: 11254448
[TBL] [Abstract][Full Text] [Related]
19. Ser217Leu polymorphism of the HPC2/ELAC2 gene associated with prostatic cancer risk in Japanese men.
Takahashi H; Lu W; Watanabe M; Katoh T; Furusato M; Tsukino H; Nakao H; Sudo A; Suzuki H; Akakura K; Ikemoto I; Asano K; Ito T; Wakui S; Muto T; Hano H
Int J Cancer; 2003 Nov; 107(2):224-8. PubMed ID: 12949798
[TBL] [Abstract][Full Text] [Related]
20. Loss of heterozygosity on chromosome 2 in Japanese patients with prostate cancer.
Ueda T; Komiya A; Suzuki H; Shimbo M; Sakamoto S; Imamoto T; Akakura K; Shiraishi T; Ichikawa T
Prostate; 2005 Aug; 64(3):265-71. PubMed ID: 15717310
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
